<p>C57BL/6 mice (n = 4) were immunized three times with 100 µg of OVA in CAF01, Al(OH)3, Montanide, MPL, CFA/2×IFA boosting with a two-week interval. A) Three weeks after the last immunization, the number of OVA-specific cells was assessed by IFN-γ ELISPOT. Mean spot-forming units (SFU) upon stimulation with 5 µg of OVA per million cells ± SEM for each group is shown. B) SFU per million cells ± SEM upon stimulation with 5 µg of OVA CD4 T cell epitope. C) SFU per million cells ± SEM upon stimulation with 5 µg of OVA CD4 T cell epitope. D) Sera were analysed for the presence of OVA-specific IgG1, E) IgG2b, F) IgG2c antibodies by ELISA. Mean EC50 ± SEM is shown. Values marked with an asterisk are significantly different (*, <i>p</i><0.05; **, ...
<p>Groups of C57BL/6 mice (9/group) were immunized nasally with 30 µg OVA-pσ1(s) alone, 30 µg OVA-pσ...
<p>C57BL/6 mice were immunized with PBS, OVA, fucoidan or OVA + fucoidan on days 0, 15 and 30. On da...
<p>Mice immunized with OVA +/− HLT adjuvants were challenged with 5×10<sup>6</sup> CFU of recombinan...
<p>(A) Anti-OVA tIgG titers of C57BL/6 mice immunized with 100 µg OVA plus the indicated doses of DM...
<p>Mice were immunized three times i.p. with 20 µg Gag p24 protein alone (‘no adjuvant’) or adjuvant...
C57BL/6 mice (n = 10/group) were immunized i.m. with ovalbumin (20 μg) with or without adjuvant on d...
<p>C3H/HeN and C3H/Hen mice were intranasally immunized with OVA plus 500 µg of PMB 3 times at weekl...
<p>IFN-γ ELISPOT responses against (A) HLA-A2-restricted CD8 T cell epitope Vif<sub>101</sub> and (B...
<p>C57BL/6 mice were immunized i.p with PBS, OVA or OVA + fucoidan on days 0, 15, 30. On day 35, ser...
<p>IFN-γ ELISPOT analysis (<b>A-C</b>) and IFN-γ ELISA (<b>D-F</b>) were performed on peripheral blo...
<p>AFCo2 or PLc (100 µg) was admixed with 20 µg of OVA and administered by i.n route to BALB/c mice....
<p>Groups of BALB/c mice were immunized 3 times i.m. (separated by 4 weeks each) with 2 different do...
<p>(A) OVA-specific and (B) βGal-specific IgG in B6 mice (n = 5) gene gun-immunized with the fusion ...
<p>Mice were immunized vaginally with 20 nm NP-Ova or PBS (control), then s.c. boosted with 300 µg O...
<p>C57BL/6 mice were immunized 3x with 2.5 µg, 5 µg, or 20 µg of rCSP (CSP-1) formulated in differen...
<p>Groups of C57BL/6 mice (9/group) were immunized nasally with 30 µg OVA-pσ1(s) alone, 30 µg OVA-pσ...
<p>C57BL/6 mice were immunized with PBS, OVA, fucoidan or OVA + fucoidan on days 0, 15 and 30. On da...
<p>Mice immunized with OVA +/− HLT adjuvants were challenged with 5×10<sup>6</sup> CFU of recombinan...
<p>(A) Anti-OVA tIgG titers of C57BL/6 mice immunized with 100 µg OVA plus the indicated doses of DM...
<p>Mice were immunized three times i.p. with 20 µg Gag p24 protein alone (‘no adjuvant’) or adjuvant...
C57BL/6 mice (n = 10/group) were immunized i.m. with ovalbumin (20 μg) with or without adjuvant on d...
<p>C3H/HeN and C3H/Hen mice were intranasally immunized with OVA plus 500 µg of PMB 3 times at weekl...
<p>IFN-γ ELISPOT responses against (A) HLA-A2-restricted CD8 T cell epitope Vif<sub>101</sub> and (B...
<p>C57BL/6 mice were immunized i.p with PBS, OVA or OVA + fucoidan on days 0, 15, 30. On day 35, ser...
<p>IFN-γ ELISPOT analysis (<b>A-C</b>) and IFN-γ ELISA (<b>D-F</b>) were performed on peripheral blo...
<p>AFCo2 or PLc (100 µg) was admixed with 20 µg of OVA and administered by i.n route to BALB/c mice....
<p>Groups of BALB/c mice were immunized 3 times i.m. (separated by 4 weeks each) with 2 different do...
<p>(A) OVA-specific and (B) βGal-specific IgG in B6 mice (n = 5) gene gun-immunized with the fusion ...
<p>Mice were immunized vaginally with 20 nm NP-Ova or PBS (control), then s.c. boosted with 300 µg O...
<p>C57BL/6 mice were immunized 3x with 2.5 µg, 5 µg, or 20 µg of rCSP (CSP-1) formulated in differen...
<p>Groups of C57BL/6 mice (9/group) were immunized nasally with 30 µg OVA-pσ1(s) alone, 30 µg OVA-pσ...
<p>C57BL/6 mice were immunized with PBS, OVA, fucoidan or OVA + fucoidan on days 0, 15 and 30. On da...
<p>Mice immunized with OVA +/− HLT adjuvants were challenged with 5×10<sup>6</sup> CFU of recombinan...